BofA Downgrades Biohaven to Underperform, Cuts Price Target to $11 on Kv7 Risks
Analyst highlights competition risk in Kv7 epilepsy program and cuts peak sales forecast.
/ 11 items
#BHVN↓
Biohaven Shares Surge as New Drugs Deliver Breakthrough Results in Graves’ Disease and IgA Nephropathy
Biohaven shares rose after strong early results from 2 drugs that quickly lower harmful antibodies in autoimmune diseases.
Analysts Turn Bullish on Biohaven, Caris, and Veracyte
Canaccord says Biohaven is undervalued and could rise on epilepsy trial results. Jefferies likes Caris Life Sciences and Veracyte, citing strong growth in cancer diagnostics and solid finances.
Goldman Sachs Starts Coverage on Biohaven with Buy Rating
Goldman Sachs initiates coverage on Biohaven with a Buy rating and $23 price target, highlighting BHV-1400 and its potential in the large IgA nephropathy market.
RBC Capital Turns Bullish on Biohaven: Big Upgrade and Higher Price Target
RBC Capital upgrades Biohaven to Outperform, raises price target to $22, and highlights improving data, lower risk, and strong 2026 catalysts.
BofA Raises Biohaven Price Target to $15 on Pipeline Progress, But Stays Cautious
Bank of America upgrades Biohaven's price target by 50% following positive pipeline updates, but maintains neutral rating citing uncertain 2026 catalysts.